Anticoagulant Therapy to Prevent Embolization

Title: Anticoagulant Therapy to Prevent Embolization

Authors: Umme Salma Durbar, Dr Naufal Rizwan

DOI: http://dx.doi.org/10.18535/jmscr/v4i7.05

Abstract

References

Corresponding Author

Abstract

Aim: This article aims at providing an overview regarding the anticoagulant therapy to prevent embolisation.
Objective: To provide a comprehensive review on anticoagulant therapy and other treatment options to prevent embolisation.

Background: An embolism is the lodging of an embolus, which may be a blood clot, fat globule, air bubble or foreign material in the bloodstream, resulting in a blockage of the blood flow to a paricular organ. Based on the organ affected, it is classified as pulmonary embolism, brain embolism, retinal embolism etc. Anticoagulants are a group of drugs that reduces the body's ability to form clots in the blood and thus they play a great role in both the prevention and treatment of established embolism. Therapeutic uses of anticoagulants include atrial fibrillation (AF), artificial heart valves, deep vein thrombosis (DVT), pulmonary embolism (PE), embolic stroke and myocardial infarction with a large mural thrombus etc. Anticoagulant drugs affect the blood's ability to clot and therefore there is also an increased risk of bleeding for people who are taking them. This article aims at providing information regarding anticoagulant therapy to prevent embolisation.

Reason: To know about the indications and use and disadvantages of anticoagulant therapy in various systemic diseases to prevent embolisation.

References

1. Guide to Anticoagulant Therapy: Heparin. A Statement for Healthcare Professionals From the American Heart Association. Jack Hirsh, MD; Sonia S. Anand, MD; Jonathan L. Halperin, MD; Valentin Fuster, MD, PhD

2. http://www.umassmed.edu/strokestop/module_one/thrombus_embolus.html

3. Anticoagulation Drug Therapy: A Review Katherine Harter, MD, Michael Levine, MD, and Sean O. Henderson, MD. West J Emerg Med. 2015 Jan; 16(1): 11–17.

4. Adams CD, Anger KA, Greenwood BC, Fanikos J. Antithrombotic pharmacotherapy. Chapter 110. In: Irwin and Rippe’s intensive care medicine. 7th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2012. p. 1224–42.

5. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141:24S–43S.

6. Weitz DS, Weitz JI. Update on heparin: What do we need to know? J Thromb Thrombolysis. 2010;29:199–207.

7. Bussey H, Francis J, Heparin Consensus Group. Heparin overview and issues. Pharmacotherapy. 2004;24:103S–7S.

8. Barrowcliffe TW. Low molecular weight heparins. Br J Haematol. 1995;90:1–7.

9. Buller HR, Davidson BL, Decousus H, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140:867–73.

10. Di Nisio M, Middeldorp A, Buller HR. Direct thrombin inhibitors. N Engl J Med. 2005;353:1028–40.

11. Adams CD, Anger KA, Greenwood BC, Fanikos J. Antithrombotic pharmaco-therapy. Chapter 110. In: Irwin and Rippe’s intensive care medicine. 7th ed. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2012. p. 1224–42.

12. Ageno W, Gallus AS, Wittkowsky A, et al. Oral Anticoagulant Therapy: Antithrombo-tic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physi-cians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:44S–88S.

13. Boehringer Ingelheim. Pradaxa (dabigatran etexilate) Package Insert. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (2012). Accessed 2 Jan 2013.

14. Spinler BE, Baetz SA. Dabigatran etexilate:an oral direct thrombin inhibitor for prophylaxis &treatment of thromboembolic diseases Pharmacotherapy 2008;28:1354–73.

15. Gulseth MP, Michaud J, Nutescu EA. Rivaroxaban: an oral direct inhibitor of factor Xa. Am J Health-Syst Pharm. 2008;65:1520–9.

16. Simpson D, Siddiqui MA, Scott LJ, et al. Reteplase: a review of its use in the management of thrombotic occlusive disorders. Am J Cardiovasc Drugs. 2006;6:265–85.

17. Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart.2003;89:1358–62.

18. Anticoagulation Therapy / Blood Thinners. Written by Dr. Simi Paknikar. Medically Reviewed by Dr Sunil Shroff on Feb01, 16

19. Atrial fibrillation: Risk of embolization. Authors; Warren J Manning,MD, Daniel E Singer, MD.

20. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S.

21. Stroke Anticoagulation and Prophylaxis Author: Salvador Cruz-Flores, MD, MPH, FAHA, FCCM, FAAN, FACP, FANA; Chief Editor: Helmi L Lutsep, MD

22. Anticoagulation Therapy / Blood Thinners. Written by Dr. Simi Paknikar. Medically Reviewed by Dr. Sunil Shroff on Feb 01, 2016.

23. Usefulness of Anticoagulant Therapy in the Prevention of Embolic Complications in Patients with Acute Infective Endocarditis . Seung-Jae Lee, Sam-Sae Oh, Dal-Soo Lim, Suk-Keun Hong, Rak-Kyeong Choi, and Jin-Sik Park BioMed Research International . Volume 2014 (2014), Article ID 254187.

24. Pulmonary Embolism Medication Author: Daniel R Ouellette, MD, FCCP; Chief Editor: Zab Mosenifar, MD, FACP, FCCP

25. Konstantinides SV, Torbicki A, Agnelli G et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014;35:3033–3069.

26. Antithrombotic therapy for prosthetic heart valves: Indications Authors; Gerard P Aungemma,MD; Barbara A Konkle,MD; William H Gaasch,MD

27. Vincent JL, De Backer D. Does disseminated intravascular coagulation lead to multiple organ failure?. Crit Care Clin. 2005 Jul. 21(3):469-77.

28. Disseminated Intravascular Coagulation Medication Author: Marcel M Levi, MD; Chief Editor: Srikanth Nagalla, MBBS, MS, FACP

29. http://www.nhs.uk/Conditions/Anticoagulant-medicines/Pages/Side-effects.aspx

30. Anticoagulants: A Review of the Pharmacology, Dosing, and Complications Current Emergency and Hospital Medicine Reports, June 2013, Volume 1, Issue 2, pp 83–97. DOI: 10.1007/s40138-013-0014-6.

Abstract

References

Corresponding Author

Call For Paper Volume 12 Issue 12 December 2024

JMSCR Menu

Impact Factor SJIF 2024: 7.892

Crossref - DOI

Editorial Policy

Frequency of Publication

Submission of Articles

Search